Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial

早产儿视网膜病变 医学 儿科 血管抑制剂 随机对照试验 激光治疗 胎龄 内科学 怀孕 贝伐单抗 激光器 化疗 遗传学 生物 物理 光学
作者
Andreas Stahl,Domenico Lepore,Alistair R. Fielder,Brian W. Fleck,James D. Reynolds,Michael F. Chiang,Jun Li,Melissa Liew,Rainer Maier,Qi Zhu,Neil Marlow
出处
期刊:The Lancet [Elsevier BV]
卷期号:394 (10208): 1551-1559 被引量:360
标识
DOI:10.1016/s0140-6736(19)31344-3
摘要

Despite increasing worldwide use of anti-vascular endothelial growth factor agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular efficacy, the appropriate drug and dose, the need for retreatment, and the possibility of long-term systemic effects. We evaluated the efficacy and safety of intravitreal ranibizumab compared with laser therapy in treatment of ROP.This randomised, open-label, superiority multicentre, three-arm, parallel group trial was done in 87 neonatal and ophthalmic centres in 26 countries. We screened infants with birthweight less than 1500 g who met criteria for treatment for retinopathy, and randomised patients equally (1:1:1) to receive a single bilateral intravitreal dose of ranibizumab 0·2 mg or ranibizumab 0·1 mg, or laser therapy. Individuals were stratified by disease zone and geographical region using computer interactive response technology. The primary outcome was survival with no active retinopathy, no unfavourable structural outcomes, or need for a different treatment modality at or before 24 weeks (two-sided α=0·05 for superiority of ranibizumab 0·2 mg against laser therapy). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, NCT02375971.Between Dec 31, 2015, and June 29, 2017, 225 participants (ranibizumab 0·2 mg n=74, ranibizumab 0·1 mg n=77, laser therapy n=74) were randomly assigned. Seven were withdrawn before treatment (n=1, n=1, n=5, respectively) and 17 did not complete follow-up to 24 weeks, including four deaths in each group. 214 infants were assessed for the primary outcome (n=70, n=76, n=68, respectively). Treatment success occurred in 56 (80%) of 70 infants receiving ranibizumab 0·2 mg compared with 57 (75%) of 76 infants receiving ranibizumab 0·1 mg and 45 (66%) of 68 infants after laser therapy. Using a hierarchical testing strategy, compared with laser therapy the odds ratio (OR) of treatment success following ranibizumab 0·2 mg was 2·19 (95% Cl 0·99-4·82, p=0·051), and following ranibizumab 0·1 mg was 1·57 (95% Cl 0·76-3·26); for ranibizumab 0·2 mg compared with 0·1 mg the OR was 1·35 (95% Cl 0·61-2·98). One infant had an unfavourable structural outcome following ranibizumab 0·2 mg, compared with five following ranibizumab 0·1 mg and seven after laser therapy. Death, serious and non-serious systemic adverse events, and ocular adverse events were evenly distributed between the three groups.In the treatment of ROP, ranibizumab 0·2 mg might be superior to laser therapy, with fewer unfavourable ocular outcomes than laser therapy and with an acceptable 24-week safety profile.Novartis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
2秒前
3秒前
朴素友安发布了新的文献求助20
3秒前
秋风的应助被DW采纳,获得10
4秒前
Mason完成签到,获得积分10
4秒前
丘比特的应助被嘻嘻滑呀采纳,获得10
5秒前
5秒前
Zhuzhu完成签到 ,获得积分10
5秒前
6秒前
自由的雅容完成签到,获得积分10
6秒前
6秒前
7秒前
sakura完成签到,获得积分10
7秒前
艾格发布了新的文献求助10
8秒前
shawn完成签到,获得积分10
8秒前
yh完成签到,获得积分20
8秒前
大气幻柏发布了新的文献求助10
8秒前
搜集达人的应助被朴素友安采纳,获得10
8秒前
Ava的应助被zhiruiwang采纳,获得10
9秒前
噜噜噜发布了新的文献求助10
9秒前
9秒前
合适忆枫发布了新的文献求助10
10秒前
10秒前
乔治发布了新的文献求助30
10秒前
Yan完成签到,获得积分10
12秒前
bei完成签到,获得积分10
12秒前
cy完成签到,获得积分10
13秒前
斯文以亦发布了新的文献求助10
13秒前
得闲完成签到,获得积分10
14秒前
14秒前
郭浩峰完成签到,获得积分10
14秒前
15秒前
wg发布了新的文献求助10
15秒前
16秒前
hhy发布了新的文献求助10
16秒前
17秒前
17秒前
南风喜欢发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139